Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease.

Chaparro M, Garre A, Guerra Veloz MF, Vázquez JM, De Castro ML, Leo E, Rodriguez E, Carbajo AY, Riestra S, Jiménez I, Calvet X, Bujanda L, Rivero M, Gomollón F, Benítez JM, Bermejo F, Alcaide N, Gutiérrez A, Mañosa M, Iborra M, Lorente R, Rojas-Feria M, Barreiro-de Acosta M, Kolle L, Van Domselaar M, Amo V, Argüelles F, Ramírez E, Morell A, Bernardo D, Gisbert JP.

J Crohns Colitis. 2019 Apr 12. pii: jjz070. doi: 10.1093/ecco-jcc/jjz070. [Epub ahead of print]

PMID:
30976785
2.

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.

Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F.

J Crohns Colitis. 2016 Nov;10(11):1287-1293. Epub 2016 Apr 19.

PMID:
27095751
3.

Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.

Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F.

Dig Dis Sci. 2017 Nov;62(11):3117-3122. doi: 10.1007/s10620-017-4661-4. Epub 2017 Jun 30.

4.

Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes.

Plevris N, Jones GR, Jenkinson PW, Lyons M, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Din S, Shand AG, Arnott ID, Lees CW.

Dig Dis Sci. 2018 Dec 7. doi: 10.1007/s10620-018-5406-8. [Epub ahead of print]

PMID:
30535885
5.

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.

Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M.

Dig Dis Sci. 2017 May;62(5):1305-1312. doi: 10.1007/s10620-017-4511-4. Epub 2017 Mar 9. Erratum in: Dig Dis Sci. 2017 Jun 28;:.

6.

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, Torp J, Grip O, Nilson S, Hertervig E, Lillienau J, Marsal J.

Therap Adv Gastroenterol. 2018 Oct 11;11:1756284818801244. doi: 10.1177/1756284818801244. eCollection 2018.

7.

Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.

Smits LJT, van Esch AAJ, Derikx LAAP, Boshuizen R, de Jong DJ, Drenth JPH, Hoentjen F.

Inflamm Bowel Dis. 2019 Jan 1;25(1):172-179. doi: 10.1093/ibd/izy227.

PMID:
29947795
8.

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.

Guerra Veloz MF, Vázquez Morón JM, Belvis Jiménez M, Pallarés Manrique H, Valdés Delgado T, Castro Laria L, Maldonado Pérez B, Benítez Roldán A, Perea Amarillo R, Merino V, Caunedo Álvarez Á, Argüelles Arias F.

Rev Esp Enferm Dig. 2018 Sep;110(9):564-570. doi: 10.17235/reed.2018.5368/2017.

9.

Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.

Guerrero Puente L, Iglesias Flores E, Benítez JM, Medina Medina R, Salgueiro Rodríguez I, Aguilar Melero P, Cárdenas Aranzana MJ, González Fernández R, Manzanares Martin B, García-Sánchez V.

Gastroenterol Hepatol. 2017 Nov;40(9):595-604. doi: 10.1016/j.gastrohep.2017.07.005. Epub 2017 Aug 31. English, Spanish.

PMID:
28865888
10.

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.

Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR; SECURE study group.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.

PMID:
29606564
11.

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.

Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M.

Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1290-1295. doi: 10.1097/MEG.0000000000000953.

12.

Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.

Gisbert JP, Chaparro M.

Gastroenterol Hepatol. 2018 Jun - Jul;41(6):389-405. doi: 10.1016/j.gastrohep.2018.04.005. Epub 2018 May 9. English, Spanish.

13.

Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.

Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL.

Clin Gastroenterol Hepatol. 2019 Jan 8. pii: S1542-3565(19)30009-6. doi: 10.1016/j.cgh.2018.12.036. [Epub ahead of print]

PMID:
30630103
14.

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group.

Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Erratum in: Lancet. 2017 Jun 10;389(10086):2286.

PMID:
28502609
15.

Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.

Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW.

Scand J Gastroenterol. 2018 Jun;53(6):692-699. doi: 10.1080/00365521.2018.1463391. Epub 2018 May 31.

PMID:
29852793
16.

Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study.

Kang B, Lee Y, Lee K, Choi YO, Choe YH.

Inflamm Bowel Dis. 2018 Feb 15;24(3):607-616. doi: 10.1093/ibd/izx047.

PMID:
29390113
17.

Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.

Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML.

J Crohns Colitis. 2017 Mar 1;11(3):297-304. doi: 10.1093/ecco-jcc/jjw166.

PMID:
27660339
18.

Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.

Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL.

Eur J Gastroenterol Hepatol. 2018 Jul;30(7):699-703. doi: 10.1097/MEG.0000000000001113.

PMID:
29538037
19.

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.

Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á.

World J Gastroenterol. 2018 Dec 14;24(46):5288-5296. doi: 10.3748/wjg.v24.i46.5288.

20.

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.

Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehøj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sørensen MV, Andersen LS, Grøn KL, Krogh NS, Pedersen L, Hetland ML; all departments of rheumatology in Denmark.

Ann Rheum Dis. 2017 Aug;76(8):1426-1431. doi: 10.1136/annrheumdis-2016-210742. Epub 2017 May 4.

PMID:
28473425

Supplemental Content

Support Center